Open AccessCase report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane
Author(s) -
Eriseld Krasniqi,
Giacomo Barchiesi,
Marco Mazzotta,
Laura Pizzuti,
Alberto Villa,
Maddalena Barba,
Patrizia Vici
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000021211
Subject(s) - medicine , exemestane , capecitabine , anastrozole , metastatic breast cancer , everolimus , oncology , breast cancer , tamoxifen , chemotherapy , progression free survival , aromatase inhibitor , cancer , surgery , colorectal cancer
Rationale: Within a rapidly expanding therapeutic armamentarium, the combination of everolimus (Eve) plus exemestane (Exe) utility needs to be reinstated in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–) metastatic breast cancer (MBC). Patient concerns: We herein report on a patient affected by HR+ HER2– MBC treated with radical surgery after neoadjuvant chemotherapy, who relapsed early on adjuvant tamoxifen, progressed rapidly on first line anastrozole, and failed treatment with third line capecitabine. Diagnoses: Metastatic luminal breast cancer progressed under standard endocrine therapy and chemotherapy. Interventions: Third line with Eve plus Exe was given after chemotherapy. Outcomes: Patient experienced a 5-year progression free interval. Lessons: Eve plus Exe remains a valid option in HR+HER2– MBC.